Trials / No Longer Available
No Longer AvailableNCT04289155
Individual Patient Compassionate Use of GX-I7
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Genexine, Inc. · Industry
- Sex
- —
- Age
- —
- Healthy volunteers
- —
Summary
Compassionate use of GX-I7 for patients with serious life-threatening illness that have exhausted all available therapies, with no other therapy options.
Detailed description
This program is being offered on a patient by patient basis and will require company, Institutional Review Board/Independent Ethics Committee and Single Patient IND approval.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GX-I7 | patients will receive the assigned dose of GX-I7 intramuscular injection every 4\~12 weeks |
Timeline
- First posted
- 2020-02-28
- Last updated
- 2022-03-17
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04289155. Inclusion in this directory is not an endorsement.